How do you secure your raw material supply in the ongoing COVID-19 pandemic? Our experts give tips in this expert roundtable about overcoming raw material challenges in cell & gene therapy manufacturing.
Other topics that are discussed are sterile connectivity between GMP raw materials and closed automated cell processing systems, raw material variability and stability, customization vs standardization, regulatory guidelines and how to establish a collaborative business model with your raw material supplier.
The experts in this roundtable are:
- David Digiusto, Chief Technical Officer, Semma Therapeutics
- Bernd Leistler, Vice President Production, CellGenix
- Tom Walls, Associate Director of Supply Chain, Bluebird Bio